New drug cocktail shows promise for Tough-to-Treat breast cancer
NCT ID NCT02705859
First seen Apr 17, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs—copanlisib and trastuzumab—in 26 women with advanced HER2-positive breast cancer that had worsened after prior treatments. The goal was to find the safest dose and see if the combo could shrink tumors or slow the disease. While not a cure, the approach aims to give patients more time with better disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Trials Ireland Investigative Site
Cork, Ireland
-
Cancer Trials Ireland Investigative Site
Dublin, Ireland
-
Cancer Trials Ireland Investigative Site
Galway, Ireland
Conditions
Explore the condition pages connected to this study.